Open AccessComparable immunoreactivity rates of PD‐L1 in archival and recent specimens from non‐small cell lung cancer
Author(s) -
Nakamura Yuki,
Kobayashi Tetsu,
Nishii Yoichi,
Suzuki Yuta,
Saiki Haruko,
Ito Kentaro,
Watanabe Fumiaki,
Nishihama Kota,
Yasuma Taro,
D'AlessandroGabazza Cori.,
Katsuta Koji,
Fujimoto Hajime,
Gabazza Esteban C,
Taguchi Osamu,
Hataji Osamu
Publication year - 2018
Publication title -
thoracic cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.823
H-Index - 28
eISSN - 1759-7714
pISSN - 1759-7706
DOI - 10.1111/1759-7714.12861
Subject(s) - medicine , immunohistochemistry , lung cancer , antibody , pathology , lymph node , monoclonal antibody , metastasis , cancer , oncology , immunology
Background Molecular targeted therapy including the use of monoclonal antibodies directed against the immune checkpoints PD‐L1 and PD‐1 receptor have remarkably improved the therapeutic response and survival of cancer patients. The tumor expression level of PD‐L1 can predict the response rate to checkpoint inhibitors. We evaluated whether the time interval between tumor tissue sampling/paraffinization and immunohistochemistry affects the staining level of PD‐L1 in non‐small cell lung cancer (NSCLC). Methods This study comprised 137 patients with NSCLC. Tumors were stained with 22C3 or 28‐8 antibodies. Results There was a significant correlation between the immunoreactivity rate of tumor tissues obtained using 22C3 and 28‐8 clones. No statistical difference in immunoreactivity between archival and recent samples stained either with 22C3 or 28‐8 antibodies was observed. The immunoreactivity rate achieved with 22C3 or 28‐8 antibodies significantly correlated with tumor histological type and size, but not with specimen storage time, age, gender, smoking history, clinical stage, or lymph node metastasis. Conclusion In brief, the results of this study show that the time interval between tissue sampling/paraffinization and immunohistochemical analysis has no influence on the immunoreactivity rate of PD‐L1 in NSCLC.